Companies ›Healthcare ›CSTL

CSTL — Nasdaq Pharmaceuticals

Castle Biosciences Inc

$29,79

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

898,1M USD

P/E

—

EV / Rev

1,7x

Div yield

0,00 %

Op margin

-12,4 %

ROE

-5,1 %

Net margin

-7,0 %

Debt / equity

0,02

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

$26,79

Open

—

Next earnings

2026-08-20

Ex-dividend

—

TR 1Y

—

About

Castle Biosciences is a molecular diagnostics company that generates revenue by providing test solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus, atopic dermatitis, and uveal melanoma.

Business. Castle Biosciences is a molecular diagnostics company that generates revenue by providing test solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus, atopic dermatitis, and uveal melanoma.

Classification66 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

Industry groupPharmaceuticals

Generated · model-assisted

Sell-side consensus

BUY9 analysts

9 buy0 hold0 sell

Avg 12m price target43,56

Analyst recommendations

9 analysts · consensus Buy

Buy9

Hold0

Sell0

12-month price target

43,56

Consensus of sell-side coverage.

Upcoming events

EarningsQ2 2026 earnings (confirmed · filed)2026-08-20

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

9 analysts · indicative

Ownership→

Principal Global Investors (Equity)

largest disclosed fund holder

Profitability→

-5,1 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning CSTL.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to CSTL. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ2 2026 earnings (confirmed · filed)2026-08-20
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR
Congressional trades
CongressJosh Gottheimer — Castle Biosciences, Inc. - Common2022-03-15 · Democrat · NJ · Sale · $1,001 - $15,000

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Classification66 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

Industry groupPharmaceuticals

AI synthesis

GENERATED

Castle Biosciences maintains a conservative capital structure with a debt-to-equity ratio of 0.02 and a current ratio of 6.04, indicating strong short-term liquidity coverage. The balance sheet holds $62.1 million in cash and equivalents against $91.1 million in total liabilities, with long-term debt limited to $7.2 million. Despite this liquidity buffer, the company generated negative operating cash flow of $6.9 million and negative free cash flow of $28.0 million in Q2 2026, driven by $21.1 million in capital expenditures. The market capitalization stands at $844.1 million, implying a price-to-book ratio of 2.25 and an EV/Revenue multiple of 1.71.

Profitability remains negative as the company invests in growth, reporting a net loss of $16.6 million and an operating loss of $21.5 million for the quarter. Return on equity is -5.14% and return on assets is -4.3%, reflecting the early-stage commercial or expansion phase typical of specialized diagnostics firms. The company carries an accumulated deficit of $240.9 million, offset by $711.1 million in additional paid-in capital. Stock-based compensation expense of $21.4 million in the first half of 2026 highlights the reliance on equity incentives to retain talent in a competitive sector.

Key takeaways

Strong liquidity position with a 6.04 current ratio and $62.1 million in cash, but significant cash burn of $54.6 million in H1 2026.
Negative profitability with a $16.6 million net loss in Q2 2026, driven by high operating expenses and stock-based compensation.
Medium dilution risk flagged due to potential strategic transactions and equity-based compensation practices.
Positive analyst sentiment with a mean price target of $43.56, implying substantial upside from the current $28.00 market price.
Revenue scale of $187.2 million in Q2 2026 supports a 1.71 EV/Revenue multiple, reflecting investor confidence in future growth.
Capital expenditures of $21.1 million in Q2 2026 indicate ongoing investment in infrastructure and diagnostic capabilities.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Quarterly

Annual

QUARTERLYFiled 2026-06-30

Q1 2026 · Quarter highlights

Revenue $187.2M; Operating income -$21.5M.

Revenue$187.2M

Operating income-$21.5M

Net income-$16.6M

Free cash flow-$28.0M

EPS—

Operating cash flow-$6.9M

Financials

Income statement

Revenue$187.2M

Gross profit—

Operating income-$21.5M

Net income-$16.6M

Margins

Gross margin—

Operating margin-11.5%

Net margin-8.9%

FCF margin-15.0%

Balance sheet

Total assets$561.2M

Total liabilities$91.1M

Total equity$470.0M

Cash & equivalents$62.1M

Long-term debt$7.2M

Cash flow

Operating cash flow-$6.9M

CapEx$21.1M

Free cash flow-$28.0M

SBC$21.4M

P&L flow · revenue → net income

Highlights

▍Revenue $187.2M
▍Operating income -$21.5M
▍Net margin -8.9%

Valuation FY

Market price

$29,79

Market cap

$844.1M

Enterprise valueⓘ

$587.4M

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

1.7x

EV / Op incomeⓘ

—

EV / OCFⓘ

9.1x

P / Bⓘ

2.2x

P / Tangible bookⓘ

2.2x

Tangible book

$374.9M

Net cashⓘ

$256.7M

Current ratioⓘ

6.0

Debt / equityⓘ

0.0

ROAⓘ

-4.3%

ROEⓘ

-5.1%

Cash conversionⓘ

-266.0%

CapEx / revenueⓘ

10.5%

SBC / revenueⓘ

13.3%

Dilution ratioⓘ

-1.2%

Revenue by segment

Business relationships

Business relationships4 disclosed relationships · 1 type · extracted from filings & disclosures

Subsidiaries4

EX21:23095b4157bcEX21:23095b4157bcSubsidiarie97%

EX21:58840f6f3f9fEX21:58840f6f3f9fSubsidiarie97%

EX21:bce0a187beacEX21:bce0a187beacSubsidiarie97%

EX21:f43495d6b137EX21:f43495d6b137Subsidiarie97%

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 36 %

EPS

Consensus EPS

-1,46

Predicted surprise

-0,02

Beat probability

36 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-08-01 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	-1,46
Revenue	—no estimate	—no estimate	363,8M USD
Operating income	—no estimate	—no estimate	-47,8M USD

Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution9 analysts

Strong buy5

Buy4

Hold0

Sell0

Strong sell0

12-month price target$43,56 · Median $40,00

Low $35,00High $57,00

Operating income · consensus-47,8M USD

EPS surprise

+43,3 %

reported vs consensus · beat

Revenue surprise

−5,4 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$35,00

Mean$43,56

Median$40,00

High$57,00

Spot$29,79

+46.2 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskMedium

Liquidity riskLow

Filing-based flags

Source documents mention dilution or offering risk.

Benchmarks vs cohort

Op Margin-12,4 %Bottom quartile

Net Margin-7,0 %Below median

ROE-5,1 %Below median

Capex / Rev10,5 %Best in class

D/E0,02Above median

Cash Conv-2,66Bottom quartile

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net disposed 63 666 sh21 exercises · 7 grants9 insiders

MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer · Stock option (right to buy) → Common StockDisposed 6 214 @ $2,39exercise · 2026-07-27
MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer · Stock option (right to buy) → Common StockDisposed 550 @ $2,39exercise · 2026-07-14
MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer · Stock option (right to buy) → Common StockDisposed 6 214 @ $2,39exercise · 2026-07-01
MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer · Stock option (right to buy) → Common StockDisposed 550 @ $2,39exercise · 2026-06-15
MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer · Stock option (right to buy) → Common StockDisposed 204 @ $2,39exercise · 2026-06-01
MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer · Stock option (right to buy) → Common StockDisposed 6 010 @ $2,39exercise · 2026-06-01
Olson TiffanyDirector · Restricted Stock Units → Common StockAcquired 11 766grant · 2026-05-28
Goldberg EllenDirector · Restricted Stock Units → Common StockAcquired 11 766grant · 2026-05-28
Harrison MilesDirector · Restricted Stock Units → Common StockAcquired 11 766grant · 2026-05-28
Cotton RodneyDirector · Restricted Stock Units → Common StockAcquired 11 766grant · 2026-05-28
Caple KimDirector · Restricted Stock Units → Common StockAcquired 11 766grant · 2026-05-28
BRADBURY DANIELDirector · Restricted Stock Units → Common StockAcquired 11 766grant · 2026-05-28
Cole G BradleyDirector · Restricted Stock Units → Common StockAcquired 11 766grant · 2026-05-28
Cole G BradleyDirector · Restricted Stock Units → Common StockDisposed 13 667exercise · 2026-05-22
Olson TiffanyDirector · Restricted Stock Units → Common StockDisposed 13 667exercise · 2026-05-22
Goldberg EllenDirector · Restricted Stock Units → Common StockDisposed 13 667exercise · 2026-05-22
Caple KimDirector · Restricted Stock Units → Common StockDisposed 13 667exercise · 2026-05-22
Cotton RodneyDirector · Restricted Stock Units → Common StockDisposed 13 667exercise · 2026-05-22
Harrison MilesDirector · Restricted Stock Units → Common StockDisposed 13 667exercise · 2026-05-22
BRADBURY DANIELDirector · Restricted Stock Units → Common StockDisposed 13 667exercise · 2026-05-22
MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer · Stock option (right to buy) → Common StockDisposed 420 @ $2,39exercise · 2026-05-21
Juvenal Tobin WChief Commercial Officer · Stock option (right to buy) → Common StockDisposed 11 210 @ $3,38exercise · 2026-05-21
MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer · Stock option (right to buy) → Common StockDisposed 130 @ $2,39exercise · 2026-05-20
MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer · Stock option (right to buy) → Common StockDisposed 6 214 @ $2,39exercise · 2026-05-07
MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer · Stock option (right to buy) → Common StockDisposed 550 @ $2,39exercise · 2026-04-21

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Regulatory filings
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data
Reference data

How metrics are computed

Cash Conversion Ratio
operating_cash_flow / net_income
Market Price
input from market-data provider (delayed close or quote-shim mid)
Ev To Revenue
enterprise_value / revenue
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Return On Equity
net_income / total_equity
Market Cap
market_price * shares_outstanding_diluted

Source documents

CASTLE BIOSCIENCES INC company facts · 2026-08-01
CASTLE BIOSCIENCES INC 10-Q 2026-07-30 · 2026-08-01
CASTLE BIOSCIENCES INC 10-Q 2026-05-06 · 2026-08-01
CASTLE BIOSCIENCES INC 10-K 2026-02-26 · 2026-08-01
CASTLE BIOSCIENCES INC 10-Q 2025-11-03 · 2026-08-01
8-K (sec_8k_material) on CSTL · 2026-08-01
Castle Biosciences Inc Market data — analyst estimates · 2026-08-01
Castle Biosciences Inc Market data — ESG · 2026-08-01
CASTLE BIOSCIENCES INC HA canonical relationships · 2026-08-01

Ownership & reference

Top holders

Principal Global Investors (Equity)Investment Managers · as of 2026-03-310,02 %$43M
Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,01 %$26M
Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$12M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$66M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$86M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$18M
Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$8M
American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$2M
Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$6M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$7M
AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$2M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$19M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$11M
Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,00 %$2M
Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$2M
Arrowstreet Capital, Limited PartnershipInvestment Managers · as of 2026-03-310,00 %$1M
AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$1M
Invesco QQQ TrustFunds · as of 2026-03-310,00 %$1M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$1M
JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,00 %$0M
T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
FMR LLCInstitutional Investor · as of 2026-03-310,00 %$1M
LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$0M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

Insider activity

Net selling0 buys · 57 sellsnet -$2,3M10 insiders · last 365d

MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer · Common StockSold 1 110 @ $24,13$27K · 2026-07-27
MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer · Common StockSold 10 @ $25,06$251 · 2026-07-27
MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer · Common StockSold 43 @ $25,06$1K · 2026-07-27
MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer · Common StockSold 50 @ $25,06$1K · 2026-07-27
MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer · Common StockSold 232 @ $25,06$6K · 2026-07-27
MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer · Common StockSold 268 @ $24,13$6K · 2026-07-27
MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer · Common StockSold 1 307 @ $24,13$32K · 2026-07-27
MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer · Common StockSold 5 982 @ $24,13$144K · 2026-07-27
MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer · Common StockOther 6 214 @ $2,39$15K · 2026-07-27
MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer · Common StockSold 550 @ $22,92$13K · 2026-07-14
MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer · Common StockSold 278 @ $22,92$6K · 2026-07-14
MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer · Common StockSold 1 153 @ $22,92$26K · 2026-07-14
MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer · Common StockOther 550 @ $2,39$1K · 2026-07-14
MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer · Common StockSold 1 357 @ $22,92$31K · 2026-07-14
Oelschlager Kristen MChief Operating Officer · Common StockSold 8 186 @ $24,40$200K · 2026-07-01
MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer · Common StockOther 6 214 @ $2,39$15K · 2026-07-01
Oelschlager Kristen MChief Operating Officer · Common StockSold 400 @ $24,78$10K · 2026-07-01
MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer · Common StockSold 6 214 @ $24,29$151K · 2026-07-01
MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer · Common StockSold 1 357 @ $24,29$33K · 2026-07-01
MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer · Common StockSold 1 153 @ $24,29$28K · 2026-07-01
MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer · Common StockSold 278 @ $24,29$7K · 2026-07-01
Oelschlager Kristen MChief Operating Officer · Common StockSold 8 587 @ $20,71$178K · 2026-06-16
MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer · Common StockOther 550 @ $2,39$1K · 2026-06-15
MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer · Common StockSold 550 @ $20,66$11K · 2026-06-15
MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer · Common StockSold 1 357 @ $20,66$28K · 2026-06-15

Short positioning

1.4Mshares short-4.7% vs prior

5.66days to cover

39.8%short of daily vol

89fails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

CSTLCanonical

Nasdaq · USD

Intel & risk

PredictorBeat prob36 %Surprise-0,02Full forecast →

peak dispatch · —

OSINT findings

Dilution riskMedium

Liquidity riskLow

Source documents mention dilution or offering risk.

Relationship graph

This companySectorSubsidiaries

Evidence & claims

From filings & derived data

Operating income (annual): USD -42.81MUnknown
Total liabilities (annual): USD 107.68MUnknown
Operating cash flow (annual): USD 64.35MUnknown
R&D expense (annual): USD 51.85MUnknown
Current assets (annual): USD 361.1MUnknown
Long-term debt (annual): USD 10.06MUnknown
Shareholders' equity (annual): USD 470.87MUnknown
Current liabilities (annual): USD 68.68MUnknown
Shares outstanding (annual): 29.69MUnknown
Net income (annual): USD -24.16MUnknown
Cost of revenue (annual): USD 71.03MUnknown
EPS (basic) (annual): USD-PER-SHARES -1Unknown
Cash & equivalents (annual): USD 116.73MUnknown
EPS (diluted) (annual): USD-PER-SHARES -1Unknown
Revenue (annual): USD 344.23MUnknown
Capex (annual): USD 36.02MUnknown
Total assets (annual): USD 578.56MUnknown
Operating income (annual): USD 8.67MUnknown
Shareholders' equity (annual): USD 455.83MUnknown
Shares outstanding (annual): 28.48MUnknown
Total assets (annual): USD 531.24MUnknown
Current assets (annual): USD 360.15MUnknown
R&D expense (annual): USD 52.04MUnknown
Total liabilities (annual): USD 75.4MUnknown

Showing 24 of 34 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-08-20EVENTUpcomingQ2 2026 earnings (confirmed · filed)

2026-07-31 04:36 UTCFILINGMaterial 8-K

2026-07-30 00:00 UTCTRANSCRIPTEarnings call — Q3 2026

2026-07-30EVENTQ2 2026 earnings (expected) estimated date

2026-07-27INSIDERMAETZOLD DEREK J sold 43 sh — Director, Pres. & Chief Exec. Officer ~$1k

2026-07-27INSIDERMAETZOLD DEREK J transacted 6.2k sh — Director, Pres. & Chief Exec. Officer ~$15k

2026-07-27INSIDERMAETZOLD DEREK J sold 6.0k sh — Director, Pres. & Chief Exec. Officer ~$144k

2026-07-27INSIDERMAETZOLD DEREK J sold 1.3k sh — Director, Pres. & Chief Exec. Officer ~$32k

2026-07-27INSIDERMAETZOLD DEREK J sold 232 sh — Director, Pres. & Chief Exec. Officer ~$6k

2026-07-27INSIDERMAETZOLD DEREK J sold 10 sh — Director, Pres. & Chief Exec. Officer ~$0k

2026-07-27INSIDERMAETZOLD DEREK J sold 1.1k sh — Director, Pres. & Chief Exec. Officer ~$27k

2026-07-27INSIDERMAETZOLD DEREK J sold 50 sh — Director, Pres. & Chief Exec. Officer ~$1k

2026-07-27INSIDERMAETZOLD DEREK J sold 268 sh — Director, Pres. & Chief Exec. Officer ~$6k

2026-07-27INSIDERMAETZOLD DEREK J disposed of 6.2k sh Stock option (right to buy) — Director, Pres. & Chief Exec. Officer

2026-07-14INSIDERMAETZOLD DEREK J transacted 550 sh — Director, Pres. & Chief Exec. Officer ~$1k

2026-07-14INSIDERMAETZOLD DEREK J sold 278 sh — Director, Pres. & Chief Exec. Officer ~$6k

2026-07-14INSIDERMAETZOLD DEREK J sold 1.2k sh — Director, Pres. & Chief Exec. Officer ~$26k

2026-07-14INSIDERMAETZOLD DEREK J sold 1.4k sh — Director, Pres. & Chief Exec. Officer ~$31k

2026-07-14INSIDERMAETZOLD DEREK J sold 550 sh — Director, Pres. & Chief Exec. Officer ~$13k

2026-07-14INSIDERMAETZOLD DEREK J disposed of 550 sh Stock option (right to buy) — Director, Pres. & Chief Exec. Officer

2026-07-01INSIDERMAETZOLD DEREK J sold 1.4k sh — Director, Pres. & Chief Exec. Officer ~$33k

2026-07-01INSIDERMAETZOLD DEREK J sold 278 sh — Director, Pres. & Chief Exec. Officer ~$7k

2026-07-01INSIDEROelschlager Kristen M sold 400 sh — Chief Operating Officer ~$10k

2026-07-01INSIDERMAETZOLD DEREK J transacted 6.2k sh — Director, Pres. & Chief Exec. Officer ~$15k

2026-07-01INSIDERMAETZOLD DEREK J sold 6.2k sh — Director, Pres. & Chief Exec. Officer ~$151k

2026-07-01INSIDERMAETZOLD DEREK J sold 1.2k sh — Director, Pres. & Chief Exec. Officer ~$28k

2026-07-01INSIDEROelschlager Kristen M sold 8.2k sh — Chief Operating Officer ~$200k

2026-07-01INSIDERMAETZOLD DEREK J disposed of 6.2k sh Stock option (right to buy) — Director, Pres. & Chief Exec. Officer

2026-06-30EARNINGSQuarterly results — Q1 2026 Revenue USD 187.2M · Net USD -16.6M

2026-06-16 00:00 UTCINSIDER15 insider transactions — 2026-06 · net sell $418k 3 derivative

2026-06-16INSIDEROelschlager Kristen M sold 8.6k sh — Chief Operating Officer ~$178k

2026-06-15INSIDERMAETZOLD DEREK J transacted 550 sh — Director, Pres. & Chief Exec. Officer ~$1k

2026-06-15INSIDERMAETZOLD DEREK J sold 550 sh — Director, Pres. & Chief Exec. Officer ~$11k

2026-06-15INSIDERMAETZOLD DEREK J sold 1.4k sh — Director, Pres. & Chief Exec. Officer ~$28k

2026-06-15INSIDERMAETZOLD DEREK J disposed of 550 sh Stock option (right to buy) — Director, Pres. & Chief Exec. Officer

2026-06-01INSIDERMAETZOLD DEREK J disposed of 6.0k sh Stock option (right to buy) — Director, Pres. & Chief Exec. Officer

2026-06-01INSIDERMAETZOLD DEREK J disposed of 204 sh Stock option (right to buy) — Director, Pres. & Chief Exec. Officer

2026-05-29FILING8-K filing →

2026-05-28 00:00 UTCINSIDER45 insider transactions — 2026-05 · net sell $213k 18 derivative

2026-05-28INSIDEROlson Tiffany acquired 11.8k sh Restricted Stock Units — Director

Showing the 40 most recent of 68 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread